Important new data from two clinical trials evaluating different treatment approaches in metastatic colorectal cancer provide reassurance for clinicians that current treatment choices are valid. The study data also confirm that molecular characterisation of such tumors is vital. These conclusions come from the phase III, randomized FIRE-3 and CALGB/SWOG 80405 trials. Data from these trials were presented at the European Society for Medical Oncology (ESMO) Congress, being held September…Continue
Added by Editorial Team on September 29, 2014 at 9:00pm — No Comments
Results presented at the 2014 Congress of the European Society for Medical Oncology (ESMO), being held September 26 - 30, 2014 in Madrid, Spain, shows that patients with HER2 positive breast cancer benefit less from anti-HER2 drugs when they have PIK3CA mutations. The data, on the impact of PIK3CA mutations as new data in the neoadjuvant setting was, presented by Evandro de Azambuja, MD, PhD, medical director of the Br.E.A.S.T. Data Centre, Jules Bordet…Continue
Added by Editorial Team on September 29, 2014 at 1:00pm — No Comments
According to phase III data presented at the ESMO 2014 Congress in Madrid, Spain, combining vemurafenib and cobimetinib shows better outcomes than a therapy of vemurafenib alone. The combination therapy with both BRAF inhibitor vemurafenib and MEK inhibitor cobimetinib achieved greater progression-free survival of PFS - (a measurement to see how well a new treatment works based on the length of time during and after the treatment without the disease getting worse) and response rates than…Continue
Added by Editorial Team on September 29, 2014 at 12:30pm — No Comments
Interim results from the phase IIb TARGET Trial, presented as Late-Breaking News at the annual meeting of the European Society for Medical Oncology (ESMO), being held September 26 - 30, 2014 in Madrid, Spain, shows improved survival in adenocarcinoma non-small cell lung cancer patients treated the small molecule drug conjugate (SMDC) vintafolide, being developed by Endocyte, in combination…Continue
Added by Editorial Team on September 27, 2014 at 4:30pm — No Comments
An experimental drug called nintedanib, a small molecule tyrosine kinase inhibitor (TKI) in development by Boehringer Ingelheim, in combination with standard chemotherapy with paclitaxel, causes a total remission of tumors in 50% of patients suffering from early HER-2- negative breast cancer, the most common type of breast cancer. These are the conclusions of the Phase I Clinical Trial, sponsored by the Spanish National Cancer Research Centre (CNIO). The study was published in British…Continue
Added by Editorial Team on September 10, 2014 at 7:00pm — No Comments
It's a big change in how cancer is being detected today. Compared to some high tech methods of for the detection of breast cancer, manual breast exams seem low-tech. Now scientists are developing a kind of "electronic skin" that "feels" and images small lumps that fingers can miss. Their work is funded by the National Institutes of Health (NIH). Knowing the size and shape of a lump could allow for earlier identification of breast cancer, which could save lives. The scientists describe…Continue
Added by Editorial Team on September 10, 2014 at 6:30pm — No Comments
In an article published on September 8, 2014 in the early online edition of Cancer, a peer-reviewed journal of the American Cancer Society, researchers show the need for cancer centers to invest more in palliative care services, adequate rooms for dying patients, staff training in end-of-life care, and advance-care-planning standards. The researchers recommend this approach based on results from surveyed physicians and nurses in hospitals within cancer centers in Germany showing that…Continue
Added by Editorial Team on September 8, 2014 at 5:30am — No Comments
Clostridium difficile infection (CDI), a serious illness resulting from infection of the internal lining of the colon by Clostridium difficile bacteria is estimated to cost the €3 billion (Euro) per year. Specialists expect that CDI will almost double over the next four decades.
The bacteria produce toxins that cause inflammation of the colon, diarrhea and, in some cases, death. Patients typically develop CDI after the use of broad-spectrum antibiotics that disrupt…Continue
Added by Editorial Team on September 7, 2014 at 6:00pm — No Comments
Enzalutamide (Xtandi™; Astellas Pharma Inc/Medivation, Inc; The drug was formerly known as MDV3100), a novel, oral, once-daily androgen receptor signaling inhibitor, reduces the risk of skeletal-related events compared with placebo, as well as reducing pain and increasing quality of life in men with metastatic…Continue
Added by Editorial Team on September 6, 2014 at 6:30pm — No Comments
In people with progressive radioiodine-refractory differentiated thyroid cancer progression free survival is significantly extended by lenvatinib (E7080; Eisai), an oral multiple receptor tyrosine kinase (RTK) inhibitor, compared to placebo 18.3 months vs 3.6 months. (RR-DTC) (Hazard Ratio (HR)=0.21, [95% CI, 0.14-0.31]; p<0.0001). This is the conclusion based on data from the SELECT-study, a phase III Study of LEnvatinib in Differentiated Cancer of the Thyroid, presented at the 38th…Continue
Added by Editorial Team on September 6, 2014 at 6:00pm — No Comments
Over the last decades, researchers have developed many new adjuvant and neoadjuvant treatment options for women with breast cancer. But because breast cancer is a complex disease not every patients benefits equally from the available treatment options. What's more, despite having no evidence of disease following surgery and chemotherapy/radiation, approximately 25% of resectable node-positive breast cancer patients will still relapse within three years. Increased presence of Circulating…Continue
Added by Editorial Team on September 5, 2014 at 11:30pm — No Comments
Researchers and scientists are making tremendous strides in their understanding, and as a result, treatment of cancer by searching genomes for links between genetic alterations and disease. Over the last decades, understanding the role of genetics in disease has become a central part in medical research. Hence, many studies involve the complex relationship between human genetics and various diseases and disease states.
Most of these studies have focused on the portion…Continue
Added by Editorial Team on September 5, 2014 at 10:00pm — No Comments
Researchers from The University of Manchester and The Christie NHS Foundation Trust, both part of Manchester Cancer Research Centre, confirmed that a test helping physicians to predict which ovarian cancer patients will respond to particular types of treatment is a step closer. The researchers believe that such as test can be available that such as test can be available in just a few years.
Such a test could mean that physicians would be able to distinguish which patients…Continue
Added by Editorial Team on September 5, 2014 at 9:00pm — No Comments
Micro RNAs or miRNAs, highly conserved non-protein-coding small RNA molecules that negatively regulate target messenger RNA through degradation or suppression of protein translation. They are frequently deregulated in human cancers. Studies show that the deregulation of miRNA expression is closely associated with tumorigenicity, invasion, and metastasis. Hence, over the last few years miRNAs have emerged as key therapeutic agents against cancers and are actively being evaluated in…Continue
Added by Editorial Team on September 5, 2014 at 5:30pm — No Comments
Results from a population-based case-control study, published online first in the September 5, 2014 edition of Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research (AACR), found no association between bra wearing and increased breast cancer risk among postmenopausal women.
"There have been some concerns that one of the reasons why breast cancer may be more common in developed countries compared with developing countries…Continue
Added by Editorial Team on September 5, 2014 at 4:30pm — No Comments
An new experimental regimen of once-weekly breast irradiation following lumpectomy provides more convenience to patients at a lower cost, results in better completion rates of prescribed radiation treatment. In addition, the treatment produces cosmetic outcomes comparable to the current standard of daily radiation.
This conclusion is based on interim results of the 5-year Phase II clinical trial using the experimental were presented at…Continue
Added by Editorial Team on September 4, 2014 at 10:30pm — No Comments
Since the early '90s breast conserving therapy or BCT has become generally accepted as a standard of care in the treatment of breast cancer. Studies have shown that patients who undergo BCT generally have a higher breast cancer-specific survival rate compared with those treated with mastectomy alone or mastectomy with radiation for early-stage invasive ductal carcinoma. But despite its acceptance for early stage breast cancer, barriers still exist that preclude patients from receiving…Continue
Added by Editorial Team on September 4, 2014 at 8:00pm — No Comments
Breast cancer is the top cancer among women in Singapore and an estimate of 1 in 16 Singaporean women will develop breast cancer by the age of 80 with a life-time risk of 6.5%. The incidence rate is expected to rise with increasing life expectancy and an ageing population.
The treatment and management of breast cancer in the elderly is generally differs from the treatment provided to younger women. As a result, there is a considerable controversy over what constitutes…Continue
Added by Editorial Team on September 4, 2014 at 5:00pm — No Comments
Controversy surrounds the supplementation with Soy. A great number of studies have shown that soy, inhibit breast cancer in laboratory studies. However, associations between consumption of soy-containing foods and breast cancer risk have been inconsistent in epidemiologic studies. What is known is that soy supplementation alters expression of genes associated with breast cancer. This may raise concerns that soy could have adverse effects in breast cancer, according to a new study…Continue
Added by Editorial Team on September 4, 2014 at 3:00pm — No Comments
Earlier today, U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda®; Merck, MSD outside the United States and Canada. The drug was previously know as MK-3475) at a dose of 2 mg/kg every three weeks for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab (Yervoy®; BMS/Bristol-Myers Squibb Company) and,…Continue
Added by Editorial Team on September 4, 2014 at 2:30pm — No Comments